Background: To assess a longitudinal follow-up of the prevalence of multiple sclerosis (MS) through 4 decades in the province of Ferrara, northern Italy, and reappraise the current rates on December 31, 2016. Methods: We conducted a community-based intensive prevalence study, by adopting a complete enumeration approach. MS cases were identified from administrative health data and medical records from the Units of Neurology and Motor Rehabilitation, Ferrara University Hospital, from other provincial neurological structures and from archives of the National Pension Institute and National Health Insurance scheme of the study area. Case ascertainment method and case definition are analogous to those adopted in previous surveys in the same area of study. Results: On December 31, 2016, 685 patients (478 women and 207 men) affected by definite or probable MS (Poser’s criteria) were living in the province of Ferrara (population 386,896), yielding a crude prevalence ratio of 194.91 (95% CI 180.4–209.6) per 100,000, 260.8 (95% CI 238.10–285.82) for women and 123.1 (95% CI 106.98–141.21) for men The prevalence ratio was 26.9 per 100,000 in 1978, increased to a value of 46.1 per 100,000 in 1981, 69.4 per 100,000 in 1993, 120.9 per 100,000 in 2004. Female to male ratio was 2.31 (1.2 on December 31, 1978). The mean duration of the disease at prevalence day was 17.5 ± 11.9 years (13.9 ± 10.8 years in 1978). The mean age at prevalence day was 52.04 ± 10.8 years (13.8 ± 10.8 years in 1978). Conclusion: Our study has confirmed the province of Ferrara is an area at high risk for MS, in line with epidemiological data from the regions of continental and insular Italy. The sharp increase in MS prevalence over time in this population can be imputed in part to a greater exposition to risk factors in genetically susceptible subjects but also to an increased survival and improved ascertainment. So, the results suggest that both methodologic and environmental factors are essential in determining the real distribution of MS. The need to get reliable estimates of MS prevalence must be highlighted as a public health and research priority, essential to support planning and prioritization of care services and to reduce the overall burden of chronic disease.

1.
Kurtzke JF: Epidemiology and etiology of multiple sclerosis. Phys Med Rehabil Clin N Am 2005; 16: 327–349.
2.
Compston DAS, Confavreux C: The distribution of multiple sclerosis; in Compston DAS, Lassman H, McDonald I, Miller D, Noseworthy J, Smith K, Wekerle H (eds): McAlpine Multiple Sclerosis (ed 4). London, Churchill Livingston, 2006, pp 71–103.
3.
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I: The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700–722.
4.
Kingwell E, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow SA, Fisk JD, Evans C, Béland SG, Kulaga S, Dykeman J, Wolfson C, Koch MW, Marrie RA: Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013; 13: 128.
5.
Battaglia MA, Bezzini D: Estimated prevalence of multiple sclerosis in Italy in 2015. Neurol Sci 2017: 38: 473–479.
6.
Granieri E, Casetta I, Tola MR: Epidemiology of multiple sclerosis in Italy and in southern Europe. Acta Neurol Scand Suppl 1995; 161: 60–70.
7.
Bezzini D, Battaglia MA: Multiple Sclerosis Epidemiology in Europe; in Asea A, Geraci F, Kaur P (eds): Multiple Sclerosis: Bench to Bedside. Advances in Experimental Medicine and Biology. Cham, Springer, 2017, vol 958, pp 141–159.
8.
Toncev G, Miletic Drakulic S, Knezevic Z, Boskovic Matic T, Gavrilovic A, Toncev S, Drulovic J, Pekmezovic T: Prevalence of multiple sclerosis in the Serbian district Sumadija. Neuroepidemiology 2011; 37: 102–106.
9.
Grytten N, Torkildsen Ø, Myhr KM: Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurol Scand 2015; 132: 29–36.
10.
Rosati G, Granieri E, Carreras M, Pinna L, Paolino E, Tola R, Aiello I, De Bastiani P: Multiple sclerosis in northern Italy. Prevalence in the province of Ferrara in 1978. Ital J Neurol Sci 1981; 2: 17–23.
11.
Granieri E, Tola R, Paolino E, Rosati G, Carreras M, Monetti VC: The frequency of multiple sclerosis in Italy: a descriptive study in Ferrara. Ann Neurol 1985; 17: 80–84.
12.
Granieri E, Malagù S, Casetta I, Tola MR, Govoni V, Paolino E, Monetti VC: Multiple sclerosis in Italy. A reappraisal of incidence and prevalence in Ferrara. Arch Neurol 1996; 53: 793–798.
13.
Granieri E, Economou NT, De Gennaro R, Tola MR, Caniatti L, Govoni V, Fainardi E, Casetta I: Multiple sclerosis in the province of Ferrara: evidence for an increasing trend. J Neurol 2007; 254: 1642–1648.
15.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231.
16.
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.
17.
Italian National Institute of Statistics Population Census. http://daticensimentopopolazione.istat.it/Index.aspx?lang=en. 2012, 2011 (accessed September 30, 2015 21).
18.
Waterhouse JAH, Muir CS, Correa P, Powell J: Cancer Incidence in Five Continents. Lyon, IARC 1976, vol 3, p 456.
19.
Schoenberg BS: Calculating confidence intervals for rates and ratios: simplified methods utilizing tabular values based in the Poisson distribution. Neuroepidemiology 1983; 2: 257–265.
20.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.
21.
Granieri E, Casetta I, Govoni V, Tola MR, Marchi D, Murgia SB, Ticca A, Pugliatti M, Murgia B, Rosati: The increasing incidence and prevalence of MS in a Sardinian province. Neurology 2000; 55: 842–848.
22.
Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Pirastru MI, Murgia B, Mannu L, Sanna G, Rosati G: Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol Scand 2001; 103: 20–26.
23.
Cocco E, Sardu C, Massa R, Mamusa E, Musu L, Ferrigno P, Melis M, Montomoli C, Ferretti V, Coghe G, Fenu G, Frau J, Lorefice L, Carboni N, Contu P, Marrosu MG: Epidemiology of multiple sclerosis in south-western Sardinia. Mult Scler 2011; 17: 1282–1289.
24.
Puthenparampil M, Seppi D, Rinaldi F, Federle L, Calabrese M, Perini P, Gallo P; Multiple sclerosis Epidemiology Veneto Study Group (MuSEV): Increased incidence of multiple sclerosis in the Veneto region, Italy. Mult Scler 2013; 19: 601–604.
25.
Solaro C, Ponzio M, Moran E, Tanganelli P, Pizio R, Ribizzi G, Venturi S, Mancardi GL, Battaglia MA: The changing face of multiple sclerosis: Prevalence and incidence in an -aging population. Mult Scler 2015; 21: 1244–1250.
26.
Bezzini D, Policardo L, Meucci G, Ulivelli M, Bartalini S, Profili F, Battaglia MA, Francesconi P: Prevalence of Multiple Sclerosis in Tuscany (Central Italy): A Study Based on Validated Administrative Data. Neuroepidemiology 2016; 46: 37–42.
27.
Bargagli AM, Colais P, Agabiti N, Mayer F, Buttari F, Centonze D, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Davoli M: Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. J Neurol 2016; 263: 751–759.
28.
Bellantonio P, Iuliano G, Di Blasio F, Ruggieri S: Prevalence and incidence of multiple sclerosis in Campobasso (Molise region chieftown, southern Italy). Clin Neur Neurosurg 2013; 115: 1806–1808.
29.
Grimaldi L, Palmeri B, Salemi G, Giglia G, D’Amelio M, Grimaldi R, Vitello G, Ragonese P, Savettieri G: High prevalence and fast rising incidence of multiple sclerosis in Caltanissetta, Sicily, Southern Italy. Neuroepidemiology 2007; 28: 28–32.
30.
Nicoletti A, Patti F, Lo Fermo S, Messina S, Bruno E, Quattrocchi G, Laisa P, Cilia S, Mostile G, Marziolo R, Scillieri R, Maimone D, Zappia M: Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey. Mult Scler 2011; 17: 273–280.
31.
Izquierdo G, Venegas A, Sanabria C, Navarro G: Long-term epidemiology of multiple sclerosis in the Northern Seville District. Acta Neurol Scand 2015; 132: 111–117.
32.
Otero-Romero S, Roura P, Solà J, Altimiras J, Sastre-Garriga J, Nos C, Vaqué J, Montalban X, Bufill E: Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. Mult Scler 2013; 19: 245–248.
33.
El Adssi H, Debouverie M, Guillemin F; LORSEP Group: Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture-recapture method. Mult Scler 2012; 18: 1244–1250.
34.
Kruja J, Beghi E, Zerbi D, Dobi D, Kuqo A, Zekja I, Mijo S, Kapisyzi M, Messina P: High prevalence of major neurological disorders in two Albanian communities: results of a door-to-door survey. Neuroepidemiology 2012; 38: 138–147.
35.
Caniglia-Tenaglia M, Guttmann S, Monaldini C, Manzaroli D, Volpini M, Stumpo M, Groppo E, Casetta I, Govoni V, Fonderico M, Pugliatti M, Granieri E: Multiple sclerosis in the Republic of San Marino, Italian peninsula: an incidence and prevalence study from a high-risk area. Neurol Sci 2018; 39: 1231–1236.
36.
Sironi L, Mamoli A, D’Alessandro G, Camerlingo M, Bottacchi E: Frequency of multiple sclerosis in Valle d’Aosta, 1971–1985. Neuroepidemiology 1991; 10: 66–69.
37.
Granieri E, Monaldini C, De Gennaro R, Guttmann S, Volpini M, Stumpo M, Fazio P, Casetta I: Multiple sclerosis in the Republic of San Marino: a prevalence and incidence study. Mult Scler 2007; 14: 325–329.
38.
Rosati G, Aiello I, Pirastru MI, Mannu L, -Sanna G, Sau GF, Sotgiu S: Epidemiology of multiple sclerosis in Northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians. Neuroepidemiology 1996; 15: 10–19.
39.
Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, Koch M, Makhani N, Morrow S, Fisk J, Dykeman J, Jetté N, Pringsheim T, Marrie RA: Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology 2013; 40: 195–210.
40.
Makhani N, Morrow SA, Fisk J, Evans C, Beland SG, Kulaga S, Kingwell E, Marriott JJ, Dykeman J, Jetté N, Pringsheim T, Wolfson C, Marrie RA, Koch MW: MS incidence and prevalence in Africa, Asia, Australia and New Zealand: a systematic review. Mult Scler Relat Disord 2014; 3: 48–60.
41.
Govoni V, Casetta I, Granieri E, Veronesi V, Malagù S, Tola MR, Paolino E, Fainardi E, Monetti VC, Aiello I: Mortality study on multiple sclerosis in the province of Ferrara, northern Italy, 1968 through 1989. Acta Neurol (Napoli) 1993; 15: 161–176.
42.
Kingwell E, Zhu F, Marrie RA, Fisk JD, Wolfson C, Warren S, Profetto-McGrath J, Svenson LW, Jette N, Bhan V, Nancy Yu B, Elliott L, Tremlett H: High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010). J Neurol 2015; 262: 2352–2363.
43.
Casetta I, De Mattia G, Laudisi M, Govoni V, Castellazzi M, Caniatti L, Baldi E, Groppo E, Pugliatti M, Granieri E: Descriptive epidemiology of multiple sclerosis in the province of Ferrara: a 40-year follow up of the frequency. Evidence for an increasing trend. Neurol Sci 2018;in press.
44.
D'Amico E, Leone C, Graziano G, Amato MP, Bergamaschi R, Cavalla P, Coniglio G, Di Battista G, Ferrò MT, Granella F, Granieri E, Lugaresi A, Lus G, Millefiorini E, Pozzilli C, Tedeschi G, Zappia M, Comi G, Trojano M, Lepore V, Patti F: The use of immunosuppressant therapy for multiple sclerosis in Italy: a multicenter retroprospective study. PLoS One 2016; 11: e0157721.
45.
Granieri E, Ruffolo C, Moser G, Groppo E, Cesnik E, Della Coletta E, Caniatti L, Baldi E, Govoni V, Pugliatti M, Casetta I: Epidemiological health and social study on multiple sclerosis in the Ferrara province. Neurol Sci 2015; 36(Suppl): 289S.
46.
Guillemin F, Baumann C, Epstein J, Kerschen P, Garot T, Mathey G, Debouverie M; LORSEP Group: Older age at multiple sclerosis onset Is an independent factor of poor prognosis: a population-based cohort study. Neuroepidemiology 2017; 48: 179–187.
47.
Lotti CBC, Oliveira ASB, Bichuetti DB, Castro I, Oliveira EML: Late onset multiple sclerosis: concerns in aging patients. Arq Neuropsiquiatr 2017; 75: 451–456.
48.
Westerlind H, Boström I, Stawiarz L, Landtblom AM, Almqvist C, Hillert J: New data identify an increasing sex ratio of multiple sclerosis in Sweden. Mult Scler 2014; 20: 1578–83.
49.
Boström I, Landtblom AM: Does the changing sex ratio of multiple sclerosis give opportunities for intervention? Acta Neurol Scand. 2015; 132: 42–45.
50.
Goodin DS: The epidemiology of multiple sclerosis: insights to disease pathogenesis; in Goodin DS (ed): Multiple Sclerosis and Related Disorders; in Aminoff MJ, Boller F, Swaab D (series eds): Handbook of Clinical Neurology Edinburgh London New York Oxford Philadelphia St Louis Sidney Toronto, Elsevier BV, 2014, vol 122 (3rd series), pp 231–266.
51.
Granieri E: Introduction. The epidemiologic study of exogenous factors in the etiology of multiple sclerosis. Neurology 1997; 49(suppl 2): S1–S3.
52.
Koch-Henriksen N, Sørensen PS: The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520–532.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.